Rosuvastatin (Crestor)

DRUG4 trials

Sponsors

AstraZeneca, Chinese PLA General Hospital, Gordon Bernard, Minneapolis Heart Institute Foundation

Conditions

Acute Respiratory Distress SyndromeAtherosclerosisCoronary Heart DiseaseH1N1 InfluenzaHypercholesterolemiaHyperlipidemiaInfluenzaStatin

Phase 3

12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

CompletedNCT00525824

AstraZenecaAtherosclerosis, Coronary Heart Disease, Hypercholesterolemia

Start: 2007-08-31End: 2008-09-30Updated: 2011-05-13

Phase 4

Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)

Chinese PLA General HospitalAtherosclerosis, Hyperlipidemia

Start: 2009-03-31End: 2012-03-31Target: 60Updated: 2010-05-27

DESIFOR-EXPAND (MHIF)

RecruitingNCT06804980

Minneapolis Heart Institute FoundationStatin, Statin Adverse Reaction, Statin Therapy

Start: 2025-02-01End: 2026-12-31Target: 100Updated: 2025-02-03

Unknown Phase

STIP: Statin Trial for Influenza Patients

TerminatedNCT00970606

Gordon BernardAcute Respiratory Distress Syndrome, H1N1 Influenza, Influenza

Start: 2009-10-31End: 2011-07-31Updated: 2017-03-22

Related Papers

Early decrease in carotid plaque lipid content as assessed by magnetic resonance imaging during treatment of rosuvastatin

BMC Cardiovascular Disorders2014-07-1421 citations

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.

2013-11-0131 citations